Subtype
Malignant Neoplasm of Unknown Primary
CI-CAN-00001150CUPExplore in graph →
4,163 active trials54 approved drugs532 evidence items
- NCIt
- C8566
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001150CUPExplore in graph →
Clinical trials
14,260 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,895)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03574818 | Necitumumab in the Neoadjuvant Setting With Gemcitabine in Surgically Resectable - 14X-US-I001 | terminated | Phase 2 | 1 | Montefiore Medical CenterOTHER | 1 | Mar 18, 2020 | clinicaltrials |
| NCT01110226 | Trial Of Cisplatin And KML-001 in Platinum Responsive Malignancies(0805GCC) | terminated | Phase 1 | 23 | University of Maryland, BaltimoreOTHER | 1 | Mar 17, 2020 | clinicaltrials |
| NCT02819999 | A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer | terminated | Phase 1 | 28 | AbbVieINDUSTRY | 1 | Mar 12, 2020 | clinicaltrials |
| NCT01760616 | Huaier Granule for Prevention of Disease Progression of Hepatocarcinoma After Non-radical Hepatectomy | terminated | Phase 4 | 790 | Qidong Gaitianli Medicines Co., LtdINDUSTRY | 1 | Mar 6, 2020 | clinicaltrials |
| NCT02452424 | A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors | terminated | Phase 1 / Phase 2 | 78 | Daiichi SankyoINDUSTRY | 1 | Mar 5, 2020 | clinicaltrials |
| NCT00854022 | Genetic Susceptibility to Kidney Cancer | terminated | — | 6 | Baylor College of MedicineOTHER | 1 | Feb 25, 2020 | clinicaltrials |
| NCT02134912 | S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib | terminated | Phase 2 | 1 | SWOG Cancer Research NetworkNETWORK | 1 | Feb 20, 2020 | clinicaltrials |
| NCT01392352 | HYPAZ: Hypertension Induced by Pazopanib(HYPAZ) | terminated | Phase 2 | 31 | Cambridge University Hospitals NHS Foundation TrustOTHER | 1 | Feb 13, 2020 | clinicaltrials |
| NCT02867280 | Sorafenib Treatment in Patients With Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection | terminated | Phase 3 | 154 | Sun Yat-sen UniversityOTHER | 1 | Feb 11, 2020 | clinicaltrials |
| NCT02425683 | Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX | terminated | Phase 2 | 24 | US Oncology ResearchINDUSTRY | 1 | Feb 10, 2020 | clinicaltrials |
| NCT02576665 | A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6) | terminated | Phase 1 | 21 | Tocagen Inc.INDUSTRY | 1 | Feb 7, 2020 | clinicaltrials |
| NCT02743975 | Near-infrared Image Guided Surgery in Pancreatic Adenocarcinoma(PENGUIN) | terminated | Phase 1 / Phase 2 | 10 | University Medical Center GroningenOTHER | 1 | Jan 28, 2020 | clinicaltrials |
| NCT03463161 | Epacadostat and Pembrolizumab in Patients With Head and Neck Cancer That Have Failed Prior Immunotherapy(ORKA) | terminated | Phase 2 | 2 | University of ChicagoOTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT01431794 | Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma | terminated | Phase 1 / Phase 2 | 23 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 22, 2020 | clinicaltrials |
| NCT01707823 | Low-Dose Acetylsalicylic Acid in Treating Patients With Stage I-III Non-Small Cell Lung Cancer | terminated | Early Phase 1 | 4 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Jan 14, 2020 | clinicaltrials |
| NCT01574300 | Collaborative Advanced Stage Tissue Lung Cancer (CASTLE) Network(CASTLE) | terminated | — | 136 | Addario Lung Cancer Medical InstituteOTHER | 0 | Jan 10, 2020 | clinicaltrials |
| NCT02429089 | Study of LEE011plus Cetuximab in Patients With a Cancer of the Head and Neck(CETLEE011) | terminated | Phase 1 | 21 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Jan 9, 2020 | clinicaltrials |
| NCT02003092 | RX-5902 Treatment of Subjects With Triple Negative Breast Cancer | terminated | Phase 1 / Phase 2 | 18 | Rexahn Pharmaceuticals, Inc.INDUSTRY | 1 | Jan 6, 2020 | clinicaltrials |
| NCT01165658 | Study of Hypofractionated Proton Radiation Therapy in Thoracic Malignancies | terminated | Phase 1 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 2, 2020 | clinicaltrials |
| NCT02487277 | PEGPH20, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal Adenocarcinoma | terminated | Phase 2 | 3 | Andrew KoOTHER | 1 | Jan 2, 2020 | clinicaltrials |
| NCT00937768 | Leuprolide Acetate or Goserelin Acetate Compared With Observation in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy | terminated | Phase 2 | 16 | Mayo ClinicOTHER | 1 | Dec 27, 2019 | clinicaltrials |
| NCT03321903 | EPR Tumor Oximetry With CE India Ink | terminated | — | 3 | Philip SchanerOTHER | 1 | Dec 19, 2019 | clinicaltrials |
| NCT01441128 | -02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer | terminated | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Dec 17, 2019 | clinicaltrials |
| NCT00094978 | Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or Mediastinum | terminated | Phase 1 | 23 | National Cancer Institute (NCI)NIH | 1 | Dec 12, 2019 | clinicaltrials |
| NCT03382886 | Nivolumab and Bevacizumab in Patients With Advanced and or Metastatic Hepatocellular Carcinoma(NUANCE) | terminated | Phase 1 | 1 | University of UtahOTHER | 1 | Dec 12, 2019 | clinicaltrials |
| NCT00582712 | An Initial Study of Lithium in Patients With Medullary Thyroid Cancer | terminated | Phase 2 | 5 | University of Wisconsin, MadisonOTHER | 1 | Dec 9, 2019 | clinicaltrials |
| NCT00985946 | Study of Panobinostat in Patients With Neuroendocrine Tumors | terminated | Phase 2 | 15 | University of Wisconsin, MadisonOTHER | 1 | Dec 9, 2019 | clinicaltrials |
| NCT02034123 | Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma | terminated | Phase 1 | 29 | GlaxoSmithKlineINDUSTRY | 3 | Dec 6, 2019 | clinicaltrials |
| NCT00975806 | Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy in Patients With Renal Cell Carcinoma | terminated | Phase 1 / Phase 2 | 16 | CelgeneINDUSTRY | 1 | Nov 25, 2019 | clinicaltrials |
| NCT01974284 | Percutaneous Ethanol Injection for Primary Papillary Thyroid Microcarcinoma | terminated | N/A | 7 | Yale UniversityOTHER | 1 | Nov 25, 2019 | clinicaltrials |
| NCT00924066 | Ixabepilone to Treat Cervical Cancer | terminated | Phase 2 | 41 | National Cancer Institute (NCI)NIH | 1 | Nov 21, 2019 | clinicaltrials |
| NCT00537511 | A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide | terminated | Phase 1 / Phase 2 | 22 | CelgeneINDUSTRY | 2 | Nov 19, 2019 | clinicaltrials |
| NCT00670748 | Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer | terminated | Phase 2 | 45 | National Cancer Institute (NCI)NIH | 1 | Nov 19, 2019 | clinicaltrials |
| NCT02177773 | GA-68 DOTA-TOC of Somatostatin Positive Malignancies(DOTA-TOC) | terminated | Phase 1 / Phase 2 | 300 | University of California, San FranciscoOTHER | 1 | Nov 12, 2019 | clinicaltrials |
| NCT01413087 | Efficacy and Safety of BC-819 and Gemcitabine in Patients With Locally Advanced Pancreatic Adenocarcinoma(LAPC-BC-819) | terminated | Phase 2 | 12 | Anchiano Therapeutics Israel Ltd.INDUSTRY | 2 | Nov 1, 2019 | clinicaltrials |
| NCT00416793 | Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer | terminated | Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | Oct 31, 2019 | clinicaltrials |
| NCT02124850 | A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab | terminated | Phase 1 | 18 | CelgeneINDUSTRY | 1 | Oct 25, 2019 | clinicaltrials |
| NCT02323360 | A Trial on SBRT After Incomplete TAE or TACE Versus Exclusive TAE or TACE For Treatment of Inoperable HCC | terminated | N/A | 41 | Istituto Clinico HumanitasOTHER | 1 | Oct 25, 2019 | clinicaltrials |
| NCT04140409 | Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation(SCIROCCO) | terminated | Phase 4 | 10 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 0 | Oct 25, 2019 | clinicaltrials |
| NCT02795819 | Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer | terminated | Phase 1 | 6 | Virginia Commonwealth UniversityOTHER | 1 | Oct 24, 2019 | clinicaltrials |
| NCT01239342 | Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer | terminated | Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | Oct 10, 2019 | clinicaltrials |
| NCT01545817 | Everolimus Post Pazopanib Treatment in Metastatic or Advanced Renal Cell Carcinoma(CATChEz) | terminated | Phase 2 | 74 | Novartis PharmaceuticalsINDUSTRY | 2 | Oct 9, 2019 | clinicaltrials |
| NCT01253642 | Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel | terminated | Phase 2 | 11 | OHSU Knight Cancer InstituteOTHER | 1 | Oct 2, 2019 | clinicaltrials |
| NCT02062632 | Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy | terminated | Phase 2 | 5 | Mayo ClinicOTHER | 1 | Oct 1, 2019 | clinicaltrials |
| NCT02447887 | Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma (mRCC) | terminated | Phase 1 / Phase 2 | 3 | Fox Chase Cancer CenterOTHER | 1 | Sep 26, 2019 | clinicaltrials |
| NCT01599754 | Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients(ATLAS) | terminated | Phase 3 | 724 | SFJ Pharma Ltd. IIINDUSTRY | 9 | Sep 20, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Mar 18, 2020source: clinicaltrials